Cargando…

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database

IMPORTANCE: Polysubstance use is a concern for patients treated for opioid use disorder (OUD). While buprenorphine can curtail harmful opioid use, co-occurring use of nonprescribed substances, such as cocaine, methamphetamine, and other opioids, may negatively affect treatment outcomes. OBJECTIVE: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saloner, Brendan, Whitley, Penn, LaRue, Leah, Dawson, Eric, Huskey, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433604/ https://www.ncbi.nlm.nih.gov/pubmed/34505888 http://dx.doi.org/10.1001/jamanetworkopen.2021.23019

Ejemplares similares

Evaluation of Trends of Near-Real-Time Urine Drug Test Results for Methamphetamine, Cocaine, Heroin, and Fentanyl
por: Twillman, Robert K., et al.
Publicado: (2020)

The Cyclical and Evolving Nature of Methamphetamine Use: An Evaluation of Near Real-time Urine Drug Test Results
por: LaRue, Leah, et al.
Publicado: (2021)

Analysis of Urine Drug Test Results From Substance Use Disorder Treatment Practices and Overdose Mortality Rates, 2013-2020
por: Whitley, Penn, et al.
Publicado: (2022)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment
por: Stein, Bradley D., et al.
Publicado: (2023)

Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge
por: Solomon, Keisha T., et al.
Publicado: (2023)

Longitudinal cognitive development of children born to mothers with opioid and polysubstance use
por: Nygaard, Egil, et al.
Publicado: (2015)

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021
por: Thakrar, Ashish P., et al.
Publicado: (2021)

Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use
por: Winkelman, Tyler N.A., et al.
Publicado: (2018)

Synthetic Urines in a Buprenorphine Clinic
por: Embers, David M., et al.
Publicado: (2019)

Individual and Combined Association Between Prenatal Polysubstance Exposure and Childhood Risk of Attention-Deficit/Hyperactivity Disorder
por: Garrison-Desany, Henri M., et al.
Publicado: (2022)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Trends in Maternal Polysubstance Use During the COVID-19 Pandemic
por: Vignes, Katherine, et al.
Publicado: (2022)

Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine
por: Nguemeni Tiako, Max Jordan, et al.
Publicado: (2020)

The Polysubstance Overdose-Death Crisis
por: Peppin, John F, et al.
Publicado: (2020)

Trends in Cannabis Polysubstance Use During Early Pregnancy Among Patients in a Large Health Care System in Northern California
por: Young-Wolff, Kelly C., et al.
Publicado: (2022)

Associations between polysubstance use and psychiatric comorbidities
por: Fernández Fernández, R., et al.
Publicado: (2023)

Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder
por: Solmeyer, Anna R., et al.
Publicado: (2022)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients
por: Hall, Sharon M, et al.
Publicado: (2018)

Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US
por: Han, Beth, et al.
Publicado: (2021)

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program
por: Furo, Hiroko, et al.
Publicado: (2021)

Role of preexisting inhibitory control deficits vs. drug use history in mediating insensitivity to aversive consequences in a rat model of polysubstance use
por: Mathieson, Elon, et al.
Publicado: (2022)

Polysubstance use in the U.S. opioid crisis
por: Compton, Wilson M., et al.
Publicado: (2020)

Editorial: Polysubstance Abuse and Cognitive Dysfunction
por: Kluwe-Schiavon, Bruno, et al.
Publicado: (2022)

Neighborhoods and adolescent polysubstance use in Jamaica
por: Gill, Amrita, et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

29. Use of Buprenorphine for Opioid Use Disorder among US Adolescents and Young Adults During the COVID-19 Pandemic
por: Alinsky, Rachel, et al.
Publicado: (2022)

Comparative analgesic efficacy of buprenorphine or clonidine with bupivacaine in the caesarean section
por: Agarwal, Kiran, et al.
Publicado: (2010)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements
por: Nguemeni Tiako, Max Jordan, et al.
Publicado: (2023)

Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention
por: Stein, Bradley D., et al.
Publicado: (2022)

Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic
por: Alinsky, Rachel H., et al.
Publicado: (2022)

Barriers and Facilitators to Clinician Readiness to Provide Emergency Department–Initiated Buprenorphine
por: Hawk, Kathryn F., et al.
Publicado: (2020)

Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic
por: Chen, Annie Y., et al.
Publicado: (2022)

Lower buprenorphine elimination rate constant is associated with lower opioid use
por: Elarabi, Hesham Farouk, et al.
Publicado: (2022)

Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction
por: Moinaddini, Fatemeh, et al.
Publicado: (2022)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1jkiuep85sqf8bgk3qjgsph22e